Compare Vanguard Mega Cap Growth ETF (MGK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Mega Cap Growth ETF vs BIO-TECHNE Corp — how do they compare? Vanguard Mega Cap Growth ETF trades at $90.04, while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp pays a 0.44% dividend while Vanguard Mega Cap Growth ETF pays none. Which is the better fit depends on your goals.
| MGK | TECH | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $92.06 | $72.29 |
52-Week Low | $70.70 | $43.31 |
Market Cap | — | $11.24B |
Enterprise Value | — | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MGK, the Vanguard Mega Cap Growth ETF, trades at $90.79, up 0.87% on the day, with a bullish technical signal driven by strong moving average alignment. The ETF's concentrated portfolio of 69 large-cap U.S. growth stocks, heavily weighted toward technology and consumer discretionary sectors, has delivered robust historical returns. Recent news highlights its low 0.05% expense ratio and potential inclusion of high-profile stocks like SpaceX, reinforcing its appeal for growth-oriented investors seeking mega-cap exposure.
The outlook for MGK remains positive due to its focus on leading growth companies, but risks include high concentration in tech stocks and sensitivity to market volatility. Investors benefit from cost efficiency and historical outperformance, yet must monitor sector-specific downturns and valuation pressures. The ETF is suited for long-term growth strategies with tolerance for drawdowns.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
